TransMedics Group
TMDX
TransMedics Group (TMDX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.44
- EPS estimate
- $0.44
- EPS surprise
- −1.08%
- Revenue surprise
- +0.01%
- Revenue
- $189.9M
- Revenue estimate
- $189.9M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.44 | $0.44 | −1.08% | $189.9M | SEC |
| Q1 2026 | May 5, 2026 | $0.60 | $0.30 | −49.84% | $173.9M | SEC |
| Q4 2025 | Feb 24, 2026 | $0.44 | $2.62 | +500.37% | $160.8M | SEC |
| Q3 2025 | Oct 29, 2025 | $0.36 | $0.66 | +83.08% | $143.8M | SEC |
| Q2 2025 | Jul 30, 2025 | $0.45 | $0.92 | +104.44% | $157.4M | SEC |
| Q1 2025 | May 8, 2025 | $0.26 | $0.70 | +165.25% | $143.5M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.16 | $0.19 | +19.05% | $121.6M | SEC |
| Q3 2024 | Oct 28, 2024 | $0.29 | $0.12 | −59.10% | $108.8M | SEC |
| Q2 2024 | Jul 31, 2024 | $0.21 | $0.35 | +66.03% | $114.3M | SEC |
| Q1 2024 | Apr 30, 2024 | −$0.02 | $0.35 | +2221.21% | $96.9M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.07 | $0.12 | +273.41% | $81.2M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.16 | −$0.78 | −380.89% | $66.4M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.13 | −$0.03 | +77.06% | $52.5M | SEC |
| Q1 2023 | May 1, 2023 | −$0.25 | −$0.08 | +67.48% | $41.6M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.30 | −$0.21 | +29.86% | $31.4M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.41 | −$0.25 | +39.32% | $25.7M | SEC |
| Q2 2022 | Aug 1, 2022 | −$0.35 | −$0.41 | −17.85% | $20.5M | SEC |
| Q1 2022 | May 3, 2022 | −$0.38 | −$0.38 | +0.24% | $15.9M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.43 | −$0.46 | −6.88% | $9.7M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.36 | −$0.47 | −32.28% | $5.4M | SEC |
Quarterly revenue
Frequently asked questions
When did TransMedics Group (TMDX) last report earnings?
TransMedics Group last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did TMDX beat earnings estimates?
No. TransMedics Group reported EPS of $0.44 for Q2 2026 against a $0.44 estimate — a 1.08% miss.
How much revenue did TMDX report last quarter?
TransMedics Group reported $189.9M in revenue for Q2 2026, against a consensus estimate of $189.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.